Blood Purification
Immunoadsorption
Immunoadsorption is an apheresis procedure that removes antibodies from the plasma. Blood is separated into cells and plasma, the plasma passes over a column that binds immunoglobulins, above all IgG autoantibodies, and the rest returns to the patient. No replacement fluid is needed.

What is immunoadsorption?
Immunoadsorption (IA) is a form of apheresis in which the patient's blood is separated into cellular and plasma components. The plasma is then passed through a column containing protein A or antigen-specific ligands that bind immunoglobulins, in particular IgG antibodies, while other plasma proteins are preserved and returned to the patient.
That selectivity is the point. Many chronic conditions are driven by antibodies the body has made against its own receptors or tissues. Medication can dampen the immune system that produces them; immunoadsorption removes the antibodies that are already circulating, and the laboratory can show the fall the same day.
Compared with therapeutic plasma exchange, immunoadsorption does not require replacement fluids such as donor plasma or albumin, which removes the risk of allergic and transfusion-related reactions and keeps the clotting factors. Compared with H.E.L.P. apheresis, it targets a different finding: H.E.L.P. precipitates lipoproteins and fibrinogen, immunoadsorption binds antibodies. When the work-up shows both, the two can be used in one program.
How does it work?
Blood is drawn from a peripheral or central venous access and passed through a cell separator. The plasma fraction is directed through an adsorption column where immunoglobulins bind to the column matrix. The purified plasma is then recombined with the cellular components and returned to the patient.
Modern systems use two columns in alternation: while one binds antibodies, the other is rinsed and regenerated, so the plasma can pass many cycles within a single session and a large share of the circulating IgG is removed each time. Because antibodies are produced continuously, the level rises again over the following days. A course therefore consists of several sessions, spaced so that each one starts from a lower level than the last, and the antibody titer is measured before and after.
What conditions is it used for?
Used for ME/CFS and post-COVID ME/CFS with receptor autoantibodies, autoimmune neurological disease, lupus and Lyme disease with raised autoantibodies. Not for unstable circulation, bleeding or a severe infection; ACE inhibitors are switched before the first session.
Show all indications and exclusions
- ME/CFS and post-COVID ME/CFS with autoantibodies against β2-adrenergic or muscarinic receptors
- Autoimmune neurological conditions (Guillain-Barré syndrome, myasthenia gravis, CIDP, autoimmune encephalitis)
- Chronic Lyme disease with elevated autoantibody titers
- Systemic lupus erythematosus (SLE)
- Antibody-mediated transplant rejection
- Dilated cardiomyopathy with cardiac autoantibodies
- Refractory autoimmune conditions unresponsive to standard immunosuppression
Who it is not for: patients with unstable circulation, active bleeding, a severe infection at the time of the session, or veins that cannot carry the two lines. Patients on ACE inhibitors are switched before the first session, because the combination with some column materials can cause a drop in blood pressure. A physician reviews these points on the first day.
Could this belong in your plan?
That depends on your findings, not on the therapy. Write to the International Office with a short history; it requests your records afterwards, and a physician reviews them before the video consultation and tells you whether this treatment belongs in your program, and which antibodies would be tested first.
What a session feels like
Before
A nurse places the venous access, checks your vital signs and settles you into a reclining chair.
During
Your blood passes through the adsorption column, which binds antibodies, and returns to you. Mild fatigue or lightheadedness can occur; a nurse adjusts the flow.
Afterwards
A short rest, then back to your room. A course means several sessions over several days, and the antibody titer is measured again before you leave.
Evidence and safety
The evidence is strong in autoimmune neurology. In ME/CFS and post-COVID ME/CFS it is emerging and comes from one research line.
Show studies, risks and side effects
The evidence is strong in autoimmune neurology. Immunoadsorption is an established treatment for immune-mediated neuropathies, where it has been compared directly with plasma exchange (Davies et al., 2020), and the American Society for Apheresis grades its indications in neurology, nephrology and cardiology in its 2023 guideline (Connelly-Smith et al., 2023).
In ME/CFS and post-COVID ME/CFS the evidence is emerging and comes from one research line. A subset of patients carries autoantibodies against β2-adrenergic receptors, and peripheral endothelial dysfunction has been measured in the condition (Scherbakov et al., 2020). A pilot study removed those antibodies by immunoadsorption in ME/CFS patients (Scheibenbogen et al., 2018), a follow-up tested repeat immunoadsorption (Tölle et al., 2020), and after the pandemic the same group treated post-COVID ME/CFS patients with elevated β2-adrenergic receptor autoantibodies, first in an interim report (Stein et al., 2023) and then in a prospective cohort (Stein et al., 2025); a 2025 study measured the immune changes that accompany the treatment (Anft et al., 2025). These are small cohorts without a placebo arm. They identify who may respond, patients with the antibody finding, and that is the finding our work-up looks for. Outside its standard indications, immunoadsorption is an individual treatment attempt, decided with the patient after medical consultation.
Safety: a 2020 series of plasma exchange and immunoadsorption in neuroinflammatory disease found both procedures well tolerated, with mostly mild events such as a fall in blood pressure, tingling and puncture-site bruising (Dorst et al., 2020). Because immunoglobulins are removed, the body's own antibody defense is lower for some days after a course; the physician weighs this when an infection is active.
How it fits the program
Immunoadsorption answers one finding, the autoantibody. In the Long COVID and ME/CFS apheresis program the first days are the laboratory work-up, including the receptor autoantibody panel; when the panel is positive, immunoadsorption is scheduled, and when fibrinogen and lipids are raised instead, H.E.L.P. apheresis is. Around the sessions run infusion and immune therapies and, where mitochondrial function is the finding, IHHT. The same antibodies are measured again in week two. For patients from abroad, the program runs two to three weeks on the ward with a video consultation in English before travel.
Costs depend on the number of sessions. After a physician has reviewed your findings you receive a written, itemized cost overview; costs and insurance explains what it covers and how the invoice is written.
Common questions about immunoadsorption
What is the difference between immunoadsorption and plasma exchange?
Plasma exchange discards the whole plasma and replaces it with albumin or donor plasma. Immunoadsorption takes only the immunoglobulins out of the plasma and returns everything else, so no replacement fluid is needed and clotting factors and albumin are kept. It is the more selective procedure when the target is an antibody.
How is immunoadsorption different from HELP apheresis?
Both run on the same principle of separating and returning plasma, but they remove different things. H.E.L.P. apheresis precipitates LDL, lipoprotein(a) and fibrinogen. Immunoadsorption binds antibodies. When the work-up finds raised fibrinogen and lipids, H.E.L.P. is the fit; when it finds autoantibodies, immunoadsorption is.
Does immunoadsorption hurt?
Venous access in both arms is the part most patients feel. The session itself lasts 2 to 4 hours in a reclining chair; the machine works quietly, and you can read or rest. Mild fatigue, a tingling sensation or a short spell of lightheadedness can occur, and a nurse in the room adjusts the flow until it passes.
Is immunoadsorption safe?
Immunoadsorption is an established hospital procedure in neurology, nephrology and cardiology. The usual side effects are a drop in blood pressure, tingling and bruising at the puncture sites; serious events were rare in a 2020 series of plasma exchange and immunoadsorption in neuroinflammatory disease. It is not used in patients with unstable circulation or active bleeding.
How much does immunoadsorption cost?
It depends on the number of sessions in your plan, which follows from the antibody findings. After a physician has reviewed your records you receive a written, itemized cost overview with each session listed, before anything is booked. The costs page explains how estimates and invoices are written for patients from abroad.
Used in these departments
References
- Immunoadsorption to remove ß2 adrenergic receptor antibodies in Chronic Fatigue Syndrome CFS/ME. PLoS One 2018. PMID 29543914
- Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Efficacy of Repeat Immunoadsorption. J Clin Med 2020. PMID 32751659
- Observational Study of Repeat Immunoadsorption (RIA) in Post-COVID ME/CFS Patients with Elevated ß2-Adrenergic Receptor Autoantibodies: An Interim Report. J Clin Med 2023. PMID 37835071
- Efficacy of repeated immunoadsorption in patients with post-COVID ME/CFS and elevated β2-adrenergic receptor autoantibodies: a prospective cohort study. Lancet Reg Health Eur 2025. PMID 39759581
- Effect of immunoadsorption on clinical presentation and immune alterations in COVID-19-induced and/or aggravated ME/CFS. Mol Ther 2025. PMID 39797400
- Peripheral endothelial dysfunction in myalgic encephalomyelitis/chronic fatigue syndrome. ESC Heart Fail 2020. PMID 32154656
- Immunoadsorption and Plasma Exchange in Seropositive and Seronegative Immune-Mediated Neuropathies. J Clin Med 2020. PMID 32605107
- Safety and Tolerability of Plasma Exchange and Immunoadsorption in Neuroinflammatory Diseases. J Clin Med 2020. PMID 32899499
- Guidelines on the Use of Therapeutic Apheresis in Clinical Practice: The Ninth Special Issue. J Clin Apher 2023. PMID 37017433
Send a free inquiry
The initial inquiry is free of charge. The International Office reviews your message and your case directly and gets back to you.
- Phone
- +49 8061 398-0
- Hours
- Mon–Thu 08:00–17:00, Fri 08:00–14:00 German time (CET/CEST); in the US Mon–Thu 2–11 a.m. ET, Fri 2–8 a.m. ET.
Munich Airport (MUC), about 60 minutes by car.